BOSTON - Elevation Oncology, Inc. (NASDAQ:ELEV), announced the expansion of its Phase 1 clinical trial for EO-3021, a cancer therapy, with the first patient dosed in Japan. This trial is part of the company's efforts to develop treatments for solid tumors with significant unmet medical needs.
EO-3021 is a clinical-stage antibody drug conjugate (ADC) targeting Claudin 18.2, a protein frequently expressed in gastric, gastroesophageal junction, pancreatic, and esophageal cancers. The trial aims to assess the safety, tolerability, and preliminary anti-tumor activity of this therapy.
Dr. Valerie Malyvanh Jansen, Chief Medical Officer at Elevation Oncology, expressed optimism about the expansion into Japan, given the prevalence of gastric cancer in the country. Dr. Kohei Shitara, the trial's principal investigator, also conveyed hope that EO-3021 could improve patient outcomes, despite recent advancements in gastric cancer treatments.
The open-label, multi-center trial (NCT05980416) includes dose escalation and expansion studies across multiple sites in the United States and Japan. The trial's additional goal is to evaluate the relationship between Claudin 18.2 expression and objective response in patients.
Updates from the ongoing trial are expected in mid-2024, with more data anticipated in the first half of 2025. Elevation Oncology holds exclusive rights for the development and commercialization of EO-3021 outside Greater China.
This news is based on a press release statement from Elevation Oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.